Accordingly, mice harboring Suv39h1-deficient or proficient lymphomas typically entered a clinical CR in response to a single administration of CTX in vivo (i.e., all mice presented tumor-free at time-point 0 post CTX; Fig. 3c). Here, SUV39H1 is linked to neoplasm.